| A systematic review of cost-effectiveness studies reporting cost-per-DALY averted PJ Neumann, T Thorat, Y Zhong, J Anderson, M Farquhar, M Salem, ... PLoS One 11 (12), e0168512, 2016 | 72 | 2016 |
| The influence of time horizon on results of cost-effectiveness analyses DD Kim, CL Wilkinson, EF Pope, JD Chambers, JT Cohen, PJ Neumann Expert review of pharmacoeconomics & outcomes research 17 (6), 615-623, 2017 | 67 | 2017 |
| Specialty drug coverage varies across commercial health plans in the US JD Chambers, DD Kim, EF Pope, JS Graff, CL Wilkinson, PJ Neumann Health Affairs 37 (7), 1041-1047, 2018 | 59 | 2018 |
| Drugs cleared through the FDA’s expedited review offer greater gains than drugs approved by conventional process JD Chambers, T Thorat, CL Wilkinson, PJ Neumann Health Affairs 36 (8), 1408-1415, 2017 | 35 | 2017 |
| Variation in private payer coverage of rheumatoid arthritis drugs JD Chambers, CL Wilkinson, JE Anderson, MD Chenoweth Journal of Managed Care & Specialty Pharmacy 22 (10), 1176-1181, 2016 | 14 | 2016 |
| Lack of Cost-Effectiveness Analyses to Address Healthy People 2020 Priority Areas PJ Neumann, M Farquhar, CL Wilkinson, M Lowry, M Gold American journal of public health 106 (12), 2205-2207, 2016 | 8 | 2016 |
| Discrepancies between FDA-required labeling and evidence that payers cite in drug coverage policies JD Chambers, EF Pope, CL Wilkinson, PJ Neumann Journal of Managed Care & Specialty Pharmacy 24 (12), 1240-1246, 2018 | 6 | 2018 |
| Variation in the Coverage of Disease-Modifying Multiple Sclerosis Drugs Among US Payers. JD Chambers, JE Anderson, CL Wilkinson, P Rane American Journal of Pharmacy Benefits 9 (5), 2017 | 6 | 2017 |
| Estimating population health benefits associated with specialty and traditional drugs in the year following product approval JD Chambers, T Thorat, CL Wilkinson, M Salem, P Subedi, ... Applied health economics and health policy 15, 227-235, 2017 | 4 | 2017 |
| Do first-in-class drugs offer larger incremental health gains than next-in-class drugs? J Chambers, T Thorat, C Wilkinson, PJ Neumann Value in Health 19 (7), A464, 2016 | 2 | 2016 |
| Factors Predicting Restrictions on US Commercial Payer Coverage of Specialty Drugs DD Kim, E Pope, CL Wilkinson, JS Graff, PJ Neumann, JD Chambers Value in Health 21, S95, 2018 | | 2018 |
| DO PAYERS COVER CANCER AND NON-CANCER DRUGS DIFFERENTLY? EF Pope, C Wilkinson, J Chambers VALUE IN HEALTH 20 (5), A21-A21, 2017 | | 2017 |
| DO SPECIALTY DRUGS OFFER LARGER POPULATION HEALTH BENEFITS THAN NON-SPECIALTY DRUGS? T Thorat, C Wilkinson, J Chambers, PJ Neumann Value in Health 19 (3), A283, 2016 | | 2016 |
